138 related articles for article (PubMed ID: 1702812)
1. Prednisone inhibits the appearance of inflammatory mediators and the influx of eosinophils and basophils associated with the cutaneous late-phase response to allergen.
Charlesworth EN; Kagey-Sobotka A; Schleimer RP; Norman PS; Lichtenstein LM
J Immunol; 1991 Jan; 146(2):671-6. PubMed ID: 1702812
[TBL] [Abstract][Full Text] [Related]
2. Effects of prednisone on the cellular responses and release of cytokines and mediators after segmental allergen challenge of asthmatic subjects.
Liu MC; Proud D; Lichtenstein LM; Hubbard WC; Bochner BS; Stealey BA; Breslin L; Xiao H; Freidhoff LR; Schroeder JT; Schleimer RP
J Allergy Clin Immunol; 2001 Jul; 108(1):29-38. PubMed ID: 11447379
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous late-phase response to allergen. Mediator release and inflammatory cell infiltration.
Charlesworth EN; Hood AF; Soter NA; Kagey-Sobotka A; Norman PS; Lichtenstein LM
J Clin Invest; 1989 May; 83(5):1519-26. PubMed ID: 2468688
[TBL] [Abstract][Full Text] [Related]
4. Allergen-induced accumulation of eosinophils and lymphocytes in skin chambers is associated with increased levels of interleukin-4 and sVCAM-1.
Fernvik E; Halldén G; Lundahl J; Raud J; Alkner U; van Hage-Hamsten M; Grönneberg R
Allergy; 1999 May; 54(5):455-63. PubMed ID: 10380776
[TBL] [Abstract][Full Text] [Related]
5. Appearance of granulocyte-macrophage colony-stimulating factor activity at allergen-challenged cutaneous late-phase reaction sites.
Massey W; Friedman B; Kato M; Cooper P; Kagey-Sobotka A; Lichtenstein LM; Schleimer RP
J Immunol; 1993 Feb; 150(3):1084-92. PubMed ID: 8423333
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis and pharmacologic modulation of the cutaneous late-phase reaction.
Massey WA
Ann Allergy; 1993 Dec; 71(6):578-84. PubMed ID: 7505536
[TBL] [Abstract][Full Text] [Related]
7. The pattern and kinetics in human skin of erythema and mediators during the acute and late-phase response (LPR).
Reshef A; Kagey-Sobotka A; Adkinson NF; Lichtenstein LM; Norman PS
J Allergy Clin Immunol; 1989 Nov; 84(5 Pt 1):678-87. PubMed ID: 2478604
[TBL] [Abstract][Full Text] [Related]
8. Effect of short-term systemic glucocorticoid treatment on human nasal mediator release after antigen challenge.
Pipkorn U; Proud D; Lichtenstein LM; Schleimer RP; Peters SP; Adkinson NF; Kagey-Sobotka A; Norman PS; Naclerio RM
J Clin Invest; 1987 Oct; 80(4):957-61. PubMed ID: 2443539
[TBL] [Abstract][Full Text] [Related]
9. Sequential patterns of inflammatory events during developing and expressed skin late-phase reactions.
Zweiman B; Haralabatos IC; Pham NC; David M; von Allmen C
J Allergy Clin Immunol; 2000 Apr; 105(4):776-81. PubMed ID: 10756229
[TBL] [Abstract][Full Text] [Related]
10. Eosinophil infiltration into human skin is antigen-dependent in the late-phase reaction.
Litchfield TM; Smith CH; Atkinson BA; Norris PG; Elliott P; Haskard DO; Lee TH
Br J Dermatol; 1996 Jun; 134(6):997-1004. PubMed ID: 8763415
[TBL] [Abstract][Full Text] [Related]
11. The influx of inflammatory cells into nasal washings during the late response to antigen challenge. Effect of systemic steroid pretreatment.
Bascom R; Pipkorn U; Lichtenstein LM; Naclerio RM
Am Rev Respir Dis; 1988 Aug; 138(2):406-12. PubMed ID: 3195836
[TBL] [Abstract][Full Text] [Related]
12. The role of basophils in allergic disease.
Knol EF; Mul FP; Lie WJ; Verhoeven AJ; Roos D
Eur Respir J Suppl; 1996 Aug; 22():126s-131s. PubMed ID: 8871057
[TBL] [Abstract][Full Text] [Related]
13. [The changes in cell population and chemical mediators in BALF following local allergen challenge].
Sunouchi K; Adachi M; Maruyama S; Mizuno M; Tazawa K; Ishihara J; Kobayashi H; Takahashi T; Tsuji A; Maeda M
Arerugi; 1991 Jul; 40(7):660-8. PubMed ID: 1656921
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of human basophil sulfidopeptide leukotriene release: releasability defined as the ability of the basophil to respond to dimeric cross-links.
MacGlashan DW; Peters SP; Warner J; Lichtenstein LM
J Immunol; 1986 Mar; 136(6):2231-9. PubMed ID: 2419427
[TBL] [Abstract][Full Text] [Related]
15. Cetirizine inhibits skin reactions but not mediator release in immediate and developing late-phase allergic cutaneous reactions. A double-blind, placebo-controlled study.
Nielsen PN; Skov PS; Poulsen LK; Schmelz M; Petersen LJ
Clin Exp Allergy; 2001 Sep; 31(9):1378-84. PubMed ID: 11591187
[TBL] [Abstract][Full Text] [Related]
16. Effects of intensity of early response to allergen on the late phase of both the nose and skin.
Small P; Biskin N; Barrett D
Ann Allergy; 1994 Sep; 73(3):252-8. PubMed ID: 8092561
[TBL] [Abstract][Full Text] [Related]
17. Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptor.
Mullarkey MF; Leiferman KM; Peters MS; Caro I; Roux ER; Hanna RK; Rubin AS; Jacobs CA
J Immunol; 1994 Feb; 152(4):2033-41. PubMed ID: 8120405
[TBL] [Abstract][Full Text] [Related]
18. Nimesulide, a sulfonanilide nonsteroidal anti-inflammatory drug, inhibits mediator release from human basophils and mast cells.
Casolaro V; Meliota S; Marino O; Patella V; de Paulis A; Guidi G; Marone G
J Pharmacol Exp Ther; 1993 Dec; 267(3):1375-85. PubMed ID: 7505332
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory cells and mediator release during ragweed challenge: correlation between histamine content in nasal secretions and appearance of inflammatory cells.
Georgitis JW; Stone BD; Gottschlich G
Ann Allergy; 1992 May; 68(5):413-8. PubMed ID: 1375006
[TBL] [Abstract][Full Text] [Related]
20. Allergen dose dependency of the early- and late-phase cutaneous response in the cynomolgus monkey.
Tomkinson A; Morton M; Stevens L; Bowden A; Tepper J
Clin Exp Allergy; 2009 Jul; 39(7):1080-7. PubMed ID: 19400909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
